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Atherosclerosis is the leading cause of death worldwide. Over the past two decades, it has
been clearly recognized that atherosclerosis is an inflammatory disease of the arterial wall.
Accumulating data from animal experiments have supported this hypothesis, however,
clinical applications making use of this knowledge remain scarce. In spite of optimal
interventional and medical therapy, the risk for recurrent myocardial infarction remains
by about 20% over 3 years after acute coronary syndromes, novel therapies to prevent
atherogenesis or treat atherosclerosis are urgently needed. This review summarizes
selected potential molecular inflammatory targets that may be of clinical relevance. We
also review recent and ongoing clinical trails that target inflammatory processes aiming
at preventing adverse cardiovascular events. Overall, it seems surprising that translation
of basic science into clinical practice has not been a great success. In conclusion, we
propose to focus on specific efforts that promote translational science in order to improve
outcome and prognosis of patients suffering from atherosclerosis.
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ATHEROSCLEROSIS
Atherosclerosis and its consequences remain a major global chal-
lenge. Coronary artery or cerebrovascular disease represent the
leading cause of mortality worldwide (Roger et al., 2011; Go
et al., 2014). Apart from its lethal consequences such myocar-
dial infarction or stroke, atherosclerosis underlies the cause of
a huge burden of morbidity, associated with heart failure due
to ischemic heart disease or neurological impairment due to
stroke.
Over the past decades, therapeutic options to treat atheroscle-
rosis or at least prevent its consequences have been significantly
improved including new pharmacological treatments such as
novel inhibitors of platelet aggregation (Cannon et al., 2010)
but also interventional techniques such as percutaneous coronary
interventions (Meier and Timmis, 2012). However, there is still
an enormous unmet need: after 3 years, 20% of ACS patients suf-
fer from recurrent myocardial infarction despite optimal medial
therapy (Cannon et al., 2005; Stone et al., 2011). Thus, novel treat-
ment options are desperately needed in order to reduce morbidity
and mortality due to atherosclerosis (Libby et al., 2011).
A SHORT HISTORICAL REVIEW—PATHOPHYSIOLOGICAL
CONCEPTS OF ATHEROSCLEROSIS AND CURRENTLY
UNMEET NEEDS
We currently believe that atherosclerosis is an inflammatory
disease (Lusis, 2000; Glass and Witztum, 2001; Woollard and
Geissmann, 2010; Zernecke and Weber, 2010; Libby et al., 2011).
There is clear evidence that modern lifestyle with high fat
diet and lack of physical activity may promote atherosclerotic
disease, however, atherosclerosis has been around for millennia
(Leibowitz, 1970; Murphy et al., 2003). In fact, atherosclerosis
and its clinical consequences have been a longstanding problem
of mankind.
Serious research investigating the underlying causes began in
the 18th century. In 1793, Edward Jenner described hardening
and calcification of vessels (Leibowitz, 1970). In 1913, Nikolai
Anitschkow found that lipid deposition plays an important
role in vascular disease (Syverson von Gemminge-Guttenberg,
2013). Over the past decades, epidemiological studies such as the
Framingham Study have helped us to identify important cardio-
vascular risk factors including arterial hypertension or diabetes
mellitus (Hense, 2003).
It is surprising that even though Rudolph Virchow had sug-
gested atherosclerosis to be an inflammatory condition as early as
in 1856 (Virchow, 1856). It took more than a century until this
hypothesis was accepted and lead to advances of atherosclerosis
research. The idea that inflammatory processes may substan-
tially contribute to the disease process was largely forgotten. In
the mid-seventies, atherosclerosis was still thought to be caused
by mechanical or chemical endothelial injury leading to loss of
endothelial integrity, adherence of platelets to the subendothe-
lial matrix accompanied by release of humoral factors inducing
proliferation of smooth muscle cells (Ross, 1976). In the mid-
eighties, the important role of the immune system and inflamma-
tory processes during atherogenesis and disease progression was
recognized (Hansson, 1993).
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Nevertheless, atherosclerosis remains an epidemiologically
highly prevalent disease and myocardial infarction and stroke
represent the most important causes of death worldwide (Roger
et al., 2011; Go et al., 2014). Furthermore, despite great advances
in treating acute coronary syndromes and controlling risk fac-
tors leading to coronary artery disease, there is still an enormous
need for further therapies as even with optimal medical treatment
(including platelet inhibitors, beta blockers, ACE inhibitors and
statins) the recurrent rate of acute coronary syndromes remains
at 20% within 3 years (Cannon et al., 2005; Stone et al., 2011).
This creates a great burden of disease, reduction of life quality,
and a great financial pressure on societies, which need to fund
treatment and consequences of myocardial infarction and stroke
(Sampson et al., 2012; Everett et al., 2013; Sirimarco et al., 2014).
In summary, the need for novel targeted treatment options that
may help to prevent cardiovascular events is evident.
RATIONALE FOR ANTI-INFLAMMATORY THERAPY OF
ATHEROSCLEROSIS
There are several reasons that make anti-inflammatory therapy
a reasonable and promising approach to treat atherosclerotic
disease:
(1) There is a large body of experimental evidence that
atherosclerosis is an inflammatory disease (Lusis, 2000;
Glass and Witztum, 2001; Woollard and Geissmann, 2010;
Zernecke and Weber, 2010; Libby et al., 2011).
(2) The role of inflammation is underscored by the relevance
of inflammatory markers in assessing the prognosis of the
disease. As reviewed by Ridker, when looking at the most
important biomarkers predicting outcome in cardiovascu-
lar disease, markers indicating inflammation clearly prevail
(Blake and Ridker, 2001). Among these are interleukin-6,
soluble ICAM-1, serum amyloid-A, and C-reactive protein.
(3) Anti-inflammatory therapies (e.g., to treat rheumatoid
arthritis) have been associated with reduction of atheroscle-
rotic disease burden (Ridker, 2009).
BASIC MECHANISMS OF INFLAMMATION IN
ATHEROSCLEROSIS
To decide which elements of the inflammatory cascademay repre-
sent optimal targets, one has to be aware of the basic components
of the inflammatory process and their role during the disease pro-
cess. These components have been excellently reviewed recently
(Tabas and Glass, 2013).
Briefly, the inflammatory reaction comprises four functional
levels:
(1) Inducers including pattern-associated molecular patterns
(PAMPs) or danger-associated molecular patterns (DAMPs):
One has to differentiate between mechanical factors such
as shear stress (Jongstra-Bilen et al., 2006) and biochemical
factors such as low density lipoproteins (LDL) or their com-
ponents (i.e., triglycerides, cholesterol esters, phospholipids,
free cholesterol, and apolioproteins) (Gleissner et al., 2007).
Furthermore, there are factors that may involve biochemical
processes leading to physical damage such as oxidative stress
(Victor et al., 2009).
(2) Receptors such as Toll-like receptors or scavenger receptors:
A large number of receptors involved in atherogenesis has
been discussed, most prominently scavenger receptors such
as CD36 or SR-A mediating the uptake of modified LDL by
macrophages, which in turn become foam cells (Shashkin
et al., 2005).
(3) The level of signal transduction involving various types of
kinases, but also transcription factors such as NF-kB;
(4) Effectors of inflammation leading to resolution of inflamma-
tion, tissue damage, or the immune response: In this context,
a large number of cytokines has been proposed to play an
important role for atherogenesis including IL-6, TNF-α, IL-
1β, or IL-17 (Erbel et al., 2009, 2010; Micha et al., 2011; IL6R
Genetics Consortium Emerging Risk Factors Collaboration
et al., 2012).
These four levels are orchestrated by a plethora of amplifiers
such as cytokines and chemokines that modulate each step and
generate a delicate equilibrium.
In animal models, numerous pro- or anti-inflammatory
molecules have been demonstrated to be important during
atherogenesis based on data from knock out, knock in or bone
marrow transplant models. However, the number of therapeutic
targets that have actually made it into clinical practice is disap-
pointingly low. This may be due to a number of reasons: (1)
Animal models generally study lesion development. By contrast,
in clinical practice patients present with established atherosclero-
sis. Thus, the therapeutic aim is lesion stabilization (or regression)
rather than preventing lesion development (Libby and Aikawa,
2002). (2) Many animal models do not properly reflect human
disease—e.g., mice do not display plaque rupture, a key feature of
human unstable atherosclerosis. (3) Finally, the discrepancies may
result from the fact that there are substantial differences between
murine and human inflammation (Seok et al., 2013).
So, while we believe to have understood the basic prin-
ciples of atherogenesis, there is still a large gap between
basic science results derived from animal models and feasible
anti-inflammatory therapies in the clinical setting.
CURRENT STUDIES TESTING ANTI-INFLAMMATORY
AGENTS TO TREAT ATHEROSCLEROSIS
The following paragraphs provide an overview of recently com-
pleted or ongoing investigations into the effects of modulators of
inflammation on cardiovascular disease.
There are three major challenges when studying anti-
atherosclerotic therapies in clinical trials: (1) Mechanisms that
have proven to promote atherogenesis in animal models may
not be suitable to prevent lesion progression or destabilization
in humans. One example is Acyl-CoA:cholesterol acyltransferase
(ACAT) inhibition, which successfully reduces atherosclerosis in
mice or rabbits, while failing to do so in humans (Kitayama et al.,
2006; Terasaka et al., 2007; Tardif et al., 2008). (2) In clinically
stable patients, the event rate is usually quite low unless patient
numbers are high and observation times are long. This translates
into a lengthy clinical trial period and high cost for investigating
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anti-atherosclerosis drugs. (3) To circumvent this problem, many
studies have used surrogate parameters such as intima media
thickness, plasma levels of specific markers (e.g., HDL or CRP)
or plaque volume etc. as primary end points. However, in many
cases these surrogate markers have been found not to prop-
erly reflect cardiovascular outcome as seen with substantially
increased HDL levels without decrease in adverse cardiovascular
events during treatment with dalcetrapib (Schwartz et al., 2012),
a cholesterylester transfer protein (CETP) inhibitor.
We therefore specifically focus on those studies that investi-
gate cardiovascular outcome. Applying these criteria substantially
reduces the number of relevant trials (Table 1), however, it seems
to be the only way to get trustworthy results.
MODULATION OF INDUCERS
Agents that modulate inducers of atherosclerosis largely focus
on lipid metabolism (Figure 1). In fact, antioxidants, inhibitors
of lipoprotein-associated phospholipase A2 (Lp-PLA2), niacin,
and cholesterol ester transfer protein (CETP) inhibitors either
aim at decreasing LDL levels or increasing HDL levels or both.
This reflects the important role of lipids during atherogenesis.
Thus, LDL and modified forms of LDL are able to promote
leukocyte recruitment to the arterial wall (Gleissner et al., 2007).
Similarly, both native and oxidized LDL induce macrophage foam
cell formation leading to secretion of various pro-inflammatory
cytokines and chemokines that in turn promote plaque devel-
opment and destabilization (Shashkin et al., 2005; Cho et al.,
2007).
ANTIOXIDANTS
Oxidative modification of LDL has been shown to be an essential
mechanism increasing their inflammatory potential (Steinberg,
2009). Accordingly, the use of anti-oxidants may be a suit-
able approach to prevent adverse cardiovascular events. Despite
promising results of in vitro experiments with vitamin E (a
potent antioxidant), clinical trials have failed to achieve positive
results in coronary artery disease patients (Wallert et al., 2014).
Succinobucol is a probucol derivative with anti-inflammatory
and antioxidant properties (Muldrew and Franks, 2009). The
Aggressive Reduction of Inflammation Stops Events (ARISE)
study investigated whether succinobucol reduced adverse car-
diovascular events in 6000 patients early after acute coronary
syndrome. Unfortunately, succinobucol had no significant effect
on the primary endpoint (Tardif et al., 2008).
INHIBITION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
(LP-PLA2)
Modification of LDL particles can be mediated by phsopholipase
A2 (PLA2). Phospholipases may promote inflammation by
producing precursors of arachidonic acid from membrane
glycerophospholipids (Corson, 2009). Briefly, LP-PLA2 may
hydrolyse oxidized phospholipids resulting in pro-inflammatory
mediators that lead to endothial dysfunction and plaque pro-
gression (Lp-PLA2 Studies Collaboration et al., 2010). There
is a soluble form (sPLA2) and a lipoprotein-associated form
(Lp-PLA2). A large meta-analysis including 79,036 patients
demonstrated that the Lp-PLA2 mass and activity are corre-
lated with the risk for cardiovascular disease (Lp-PLA2 Studies
Collaboration et al., 2010). Darapladib inhibits Lp-PLA2 activity
by roughly 95%, has no effects on blood lipids and has been
shown to lower hs-CRP and IL-6 levels (Mohler et al., 2008).
Furthermore, both in a porcine model of atherosclerosis and in
human individuals, darapladib significantly reduces the necrotic
core of atherosclerotic plaques (Serruys et al., 2008). Accordingly,
PLA2 inhibition by dalcetrapib has been suggested to be a suitable
approach to prevent cardiovascular events.
Thus, in the STabilization Of Atherosclerotic Plaque By
Initiation of DarapLadIb TherapY (STABILITY) trial darapladib
was tested in 15,828 patients with stable CAD and one risk fac-
tor for its ability to reduce a composite endpoint consisting of
cardiovascular death, non-fatal myocardial infarction, or stroke.
Similarly, the Stabilization Of pLaques usIng Darapladib—
Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI52) trial
tested the effects of darapladib on adverse cardiovascular events
early (≤30 days) after acute coronary sondrome (13,000 patients)
(White et al., 2014). While the STABILITY failed to show a sig-
nificant effect of darapladib on adverse cardiovascular events
(White et al., 2010), results from the SOLID-TIMI52 trial are still
pending.
NIACIN
Niacin, a member of the vitamin B family, is known to lower LDL
and increase HDL levels (Jackevicius et al., 2013). Despite clear
evidence, niacin has been increasingly used in coronary artery dis-
ease patients. A large randomized controlled clinical trial has now
investigated its role as an anti-atherosclerotic drug: The effects of
niacin were studied in the Heart Protection Study 2–Treatment
of HDL to Reduce the Incidence of Vascular Events (HPS2-
THRIVE) study. In this study, 25,673 high risk CAD patients
were treated with standard lipid-lowering therapy plus placebo or
plus extended-release niacin with laropiprant for 3.9 years (Group
et al., 2014). Laropiprant was added to reduce flush symptoms
known to occur after niacin intake. Other than expected, niacin
did not affect the composite end point of major cardiovascu-
lar events, but increased the incidence of diabetes and other side
effects such as gastrointestinal, musculskeletal, or skin problems,
and infections.
CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITION
There is clear epidemiological evidence that increased high den-
sity lipoproteins (HDL) plasma levels are associated with benefi-
cial outcome in coronary artery disease (Assmann et al., 2002).
By contrast, low HDL levels are clearly correlated with adverse
cardiovascular outcome making HDL an excellent biomarker for
risk prediction (Toth et al., 2013). Therefore, HDL levels have
come into focus as a potential therapeutic target. It is thought
that HDL acts in an anti-inflammatory manner via different
pathways: Most importantly, HDL is able to mediate cholesterol
efflux frommacrophage foam cells via the cholesterol efflux trans-
porters ABCA1 and ABCG1 thereby modifying the inflammatory
response (Landmesser et al., 2012). Furthermore, HDL may have
direct anti-inflammatory effects on endothelial cells (Wu et al.,
2013) andmacrophages (DeNardo et al., 2014). Accordingly, rais-
ing HDL levels has been proposed to be beneficial and potentially
prevent adverse cardiovascular events.
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A series of studies has tested inhibitors of the CETP, which
increase HDL levels. CETP mediates the transfer of cholesteryl
esters from HDL to VLDL and LDL thereby decreasing HDL lev-
els. CETP inhibition in turn increases HDL levels. Human CETP
could be shown to increase atherosclerosis in mice (de Vries-van
der Weij et al., 2009) Furthermore, there are data suggesting that
the CETP inhibitor anacetrapib may reduce atherosclerosis and
promote plaque stability in mice (Kuhnast et al., 2014).
Two substances—torcetrapib and dalcetrapib—have been
invstigate in two large clinical trials [ILLUMINATE (15,067
patients), Dal-OUTCOMES (15,871 patients)]. In fact, both
significantly increased HDL levels, however, in the case of
torcetrapib, excess mortality was seen—most likely due to
off-target effects such as increased blood pressure (Barter
et al., 2007). By contrast, dalcetrapib significantly increased
HDL levels without modulating other cardiovascular risk fac-
tors overall resulting in no significant reduction of adverse
cardiovascular events (Schwartz et al., 2012). The effects of
anacetrapib on the course of CAD are currently under investi-
gation (REVEAL, 30,000 patients)—results are expected in 2017
(Landmesser et al., 2012).
One explanation why thus far CETP inhibition has failed
to prevent cardiovascular events may be given by a recently
published Mendelian randomization study, which showed that
genes increasing HDL levels do not decrease cardiovascular risk
(Holmes et al., 2014). Furthermore, there are increasing data sug-
gesting that HDL functionality may significantly differ between
healthy individuals and CAD patients—in fact, HDL isolated
from CAD patients may even increase inflammation via eNOS
inhibition and loss of its anti-inflammatory potential (Besler
et al., 2011). Thus, merely increasing HDL may not be sufficient
to reduce cardiovascular risk. It remains to be seen whether the
approach of CETP inhibition is feasible after all or whether the
increase of HDL achieved by CETP inhibitors will generally fail
to prevent adverse cardiovascular events. If that were the case,
other options to affect HDL may be suitable targets. However, the
focus may shift from merely increasing HDL levels to specifically
improving HDL functionality. At this point neither appropri-
ate tools to measure HDL functionality in clinical practice, nor
specific agents to affect HDL functionality are readily available.
MODULATION OF EFFECTORS
Compared to therapies that modulate inducers of atherosclerosis,
current therapeutic approaches that target modulation of effec-
tors are scarce. It is surprising to see that none of the approaches
target receptors such as CD36 or SR-A. CD36 and SR-A account
for the vast majority of modified LDL uptake (Kunjathoor et al.,
2002). SR-A is a receptor for acetylated LDL, whereas CD36
binds both acetylated LDL and oxidized LDL (Kunjathoor et al.,
2002). Deficiency of CD36 or SRA-A or both have been associated
with reduced atherogenesis in Apoe−/− mice (Babaev et al., 2000;
Febbraio et al., 2000), however, there was no additive effect on
lesion development when both were knocked out (Kuchibhotla
et al., 2008). In some of these studies, scavenger receptor defi-
ciency was associated with reduction of foam cell formation or
lesion complexity without affecting lesion size (Moore et al.,
2005; Manning-Tobin et al., 2008). These different findings may
be explained by differences in genetic backgrounds, time points
assessed, and different methods used to measure atherosclero-
sis (Witztum, 2005). Furthermore, one has to bear in mind that
receptors such as CD36 are ubiquitously expressed and relevant
to many disease processes—e.g., CD36 not only is a major recep-
tor for oxidized LDL, but also plays an important role in malaria
pathogenesis. Taken together it seems unlikely that these targets
are specific enough to achieve satisfactory results.
Similarly, it is surprising that there are no large random-
ized controlled trials investigating the effects of anti-rheumatic
drugs on atherosclerosis. For example, a retrospective cohort of
2101 rheumatoid arthritis patients showed that treatment with
methotrexate was associated with a significantly reduced inci-
dence of a combined endpoint including myocardial infarction,
unstable angina or coronary revascularization (Bili et al., 2014).
At this point, data on antibodies such as infliximab, etaner-
cept, or tocilizumab seem inconclusive: Most studies are rather
small, they investigate “soft” end points such as arterial stiff-
ness (Tam et al., 2012) or look at pre-specified patient groups
that only partially reflect “real world” patients in cardiovascular
medicine (Nieuwdorp et al., 2009; Yeh et al., 2014), some studies
are negative (Ramonda et al., 2014).
INSULIN SENSITIZERS
Insulin sensitizers are a group of drugs activating the peroxisome
proliferator-activated receptor-γ (PPARγ). It has been known
for a long time that the transcription factor PPARγ is involved
in both metabolic processes and vascular inflammation (Neve
et al., 2000). Through activation of a number of metabolic genes,
PPARγ agonists increase insulin sensitivity especially in liver,
muscle and fat tissue thereby increasing glucose uptake from the
blood. Based on pathophysiological considerations, it was postu-
lated that PPARγ not only decreases blood glucose but in addition
may decrease the risk of cardiovascular events. There are two
large randomized controlled clinical trials testing the effects of
rosiglitazone and pioglitazone on cardiovascular outcome.
In the RECORD trial, 4447 patients with type 2 diabetes on
anti-diabetic therapy were additionally treated with rosiglitazone
(Home et al., 2009). During a mean 5.5-year follow-up, rosigli-
tazone turned out to be non-inferior in regards to cardiovascular
death, myocardial infarction, or stroke (Neve et al., 2000). This
did not confirm a previously published meta-analysis that had
claimed an increase of myocardial infarction with rosiglitazone
(Nissen and Wolski, 2007).
In the PROactive study 5238 patients with type 2 diabetes and
macrovascular disease were either treated with pioglitazone or
placebo in addition to standard therapy and followed up for 2.85
years (Dormandy et al., 2005). Pioglitazone significantly reduced
the occurrence of fatal or non-fatal myocardial infarction with
a moderate p-value of 0.045. All-cause mortality and cardiac
mortality were not affected by treatment with pioglitazone. Even
though, these results were encouraging, pioglitazone should be
used with extreme caution as development of bladder cancer has
been recognized as serious side effect.
Taken together, even though being an attractive pharmaceuti-
cal principle for treating diabetes, PPARγ activation has not been
successful in clinical practice—mostly due to safety concerns.
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FIGURE 1 | Basic mechanisms of atherogenesis and studies specifically
targeting inflammation in atherogenesis.Briefly, bloodmonocytes enter the
subendothelial space where they differentiate toward macrophages and foam
cells, which in turn secrete pro-inflammatory mediators leading to further
inflammation, plaque growth and eventually plaque rupture. RECORD
(rosiglitazone) and PROActive (pioglitazone) have studied the role of
peroxysome proliferator-activated receptor-γ (PPARγ) agonists, which increase
insulin sensitivity, glucose and free fatty acid (FFA) uptake, while reducing
gluconeogenesis including anti-inflammatory effects. CANTOS (canakinumab)
and CIRT (low dose methotrexate) target IL-1β or IL-6. ARISE (succinobucol),
STABILITY and SOLID-TIMI52 (both darapladib) target oxidation of native LDL,
which significantly contributes to foam cell formation. ILLUMINATE
(torcetrapib), Dal-OUTCOMES (dalcetrapib) and REVEAL (anacetrapib) target
HDL levels via inhibition of the cholesterol ester transfer protein (CETP), which
is potentially atheroprotective. Red font: negative trial results; red-green font:
partially positive results, substance abandoned for side effects; black font:
results pending. CETP cholesterol transfer protein; FFA, free fatty acids; HDL,
high density lipoprotein; IL, interleukin; LDL, low density lipoprotein; oxLDL,
oxidized low density lipoprotein; PPAR, peroxysome proliferator-activated
receptor; VLDL, very low density lipoprotein.
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INHIBITION OF IL-1β
IL-1β may represent a suitable target to treat atherosclerosis
(Dinarello, 2009). Currently, the Canakinumab Anti-
inflammatory Thrombosis Outcome Study (CANTOS)
investigates the effects of canakinumab, a monoclonal anti-
body against IL-1β on cardiovascular events in 17,200 patients
with prior myocardial infarction. Canakinumab has initially been
developed to treat rheumatoid arthritis (Dhimolea, 2010). It has
no effects on plasma lipids, but significantly lowers markers of
inflammation such as IL-6 or CRP (Ridker et al., 2012). Results
of the CANTOS trial are expected in 2016 (Ridker et al., 2011).
INHIBITION OF THE IL-6 PATHWAY
Interleukin-6 clearly plays an important role in atherogenesis
as shown by a meta-analysis of 82 studies published in 2012
(IL6R Genetics Consortium Emerging Risk Factors Collaboration
et al., 2012). Low dose methotrexate (which partially acts on the
IL-6 pathway as demonstrated by reduction of IL-6 plasma lev-
els) has been shown to reduce cardiovascular events in patients
with rheumatoid arthritis with hazard ratios between 0.3 and
0.85 (Ridker, 2009; Micha et al., 2011). Accordingly, in the
Cardiovascular Inflammation Reduction Trial (CIRT), 7000 are
being treated with 15–20mg methotrexate per week (including
1mg of folate) or placebo (plus folate) (Everett et al., 2013). The
study will include patients with stable CAD and test the occur-
rence of a composite endpoint consisting of cardiovascular death,
non-fatal MI or stroke. Results can be expected in 2018/19.
WHY HAVE SO MANY STUDIES FAILED?
In fact, with exception of the large statin trials such as the
JUPITER study (Ridker et al., 2008), none of the approaches
to specifically treat inflammation in order to prevent or reduce
atherosclerosis in human individuals was successful. The fact that
statins have pleiotropic effects and act in an anti-inflammatory
fashion beyond lowering cholesterol can be considered a lucky
coincidence rather than due to intention (Mihos et al., 2014).
Based on the considerations made above, one has to won-
der why anti-inflammatory agents have widely failed in clinical
practice.
The first explanation is pharmacology: Off-target effects may
predominate potential anti-atherosclerotic effects as seen with
torcetrapib (Barter et al., 2007) or pioglitazone (Ferwana et al.,
2013). Furthermore, the chosen targets may be inappropriate—
e.g., they may lack specificity. In fact, it is hard to believe that
inhibition of a single specific pro-inflammatory cytokine may
result in reduced atherosclerosis without serious side effects such
as an increase of infections or neoplastic disease. On the other
hand, the pathophysiological role of the proposed targets may
simply be not be fully understood: e.g., dalcetrapib did signif-
icantly increase HDL levels, however, this did not result in a
significant reduction of adverse cardiovascular events (Schwartz
et al., 2012). Thus, HDL levels alone do not seem to be a use-
ful surrogate marker for prediction of adverse events and one
rather needs to test HDL functionality to really make use of it
as a therapeutic target (Luscher et al., 2014). Finally, a one-target
strategy may simply be insufficient to successfully treat a disease
as complex as CAD as there are redundant pathways.
CONCLUSIONS
In conclusion, the aim to prevent or treat atherosclerosis via mod-
ulating inflammation remains challenging. The efforts that have
been made so far show us two things: Firstly, the application of
data obtained from small animal models of atherosclerosis is not
necessarily pertinent to the human disease. Secondly, surrogate
markers are not necessarily good therapeutic targets to prevent
adverse clinical events. Accordingly, careful translation of results
from animal studies into the human system and large clinical
trials will be needed to successfully improve anti-inflammatory
therapy of atherosclerosis in the future. To achieve this ambitious
goal two major points need to be considered: (1) Developing ani-
mal models that properly reflect the human disease is crucial.
This specifically includes models that allow study of plaque rup-
ture and plaque regression. Rabbit models may be helpful in this
context, under specific circumstances large animal models may
similarly be suitable. Furthermore, novel molecular imaging tech-
niques may allow better insight into the events leading to plaque
rupture (Korosoglou et al., 2014). (2) Translation of animal data
into the clinical setting needs to be undertaken with extreme cau-
tion. As adverse cardiovascular events are quite rare, large studies
with long follow-up periods are needed to investigate the effects
of novel drugs on hard cardiovascular end points. In many cases,
these trials will have to be supported by governmental funding, as
industry sponsors may not be willing to risk failure of large long-
term studies. Considering the enormous impact of CAD on our
societies, it seems worthwhile pursuing this aim.
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